NBC Montana

Providence St. Patrick Hospital to participate in APOLLO research trial

MISSOULA, Mont. — Providence St. Patrick Hospital will be one of five global sites participating in the APOLLO research trial to study the device 29 French IntrepidTM transcatheter mitral valve ...
Nasdaq

Marker Therapeutics Reports Promising Results from Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma Patients

Marker Therapeutics, Inc. provided an update on its Phase 1 APOLLO study of MT-601, a novel T cell therapy targeting relapsed lymphoma patients. The study reported an objective response rate of 78% ...
Nasdaq

Marker Therapeutics, Inc. Secures $16.1 Million in Private Placement to Advance MT-601 Clinical Study for Lymphoma Treatment

Marker Therapeutics secures $16.1 million through private placement to advance MT-601 clinical trials for lymphoma treatment. Marker Therapeutics, Inc. announced the completion of a $16.1 million ...
Seeking Alpha

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both ...